
Policy & Acquisitions
Mergers & Acquisitions
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Mergers & Acquisitions
Mergers & AcquisitionsJazz Pharmaceuticals to Acquire Actio Biosciences to Expand Rare Epilepsy PortfolioJazz Pharmaceuticals will acquire Actio Biosciences for $820 million upfront plus up to $500 million in contingent payments, gaining ABS-1230, an investigational oral KCNT1 inhibitor being developed for…Fact-Checked
Mergers & AcquisitionsSobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphomaSobi and Innate Pharma partner to advance lacutamab in T-cell lymphoma, with TELLOMAK-3 Phase 3 designed to support potential accelerated…Fact-Checked
Mergers & AcquisitionsBeOne, Revolution Medicines Expand RAS(ON) Cancer Collaboration in AsiaBeOne Medicines and Revolution Medicines will evaluate combinations of BeOne oncology assets with four RAS(ON) inhibitors while expanding development and commercialization rights across selected Asian markets.Fact-Checked
Mergers & AcquisitionsEvotec, Odyssey Partner to Advance AI-Driven Small Molecule Discovery for Autoimmune and Inflammatory DiseasesEvotec and Odyssey Therapeutics have formed a strategic collaboration to discover AI-enabled small molecule therapies for autoimmune and inflammatory diseases…Fact-Checked
Mergers & AcquisitionsOno and Mediar Partner to Develop Novel Antibody Therapies for FibrosisOno Pharmaceutical and Mediar Therapeutics have entered a discovery collaboration to develop novel antibody therapeutics targeting myofibroblasts for fibro-inflammatory diseases.Fact-Checked
ManufacturingFujifilm, Taiho Partner to Advance Manufacturing of Next-Gen ADCsFUJIFILM Corporation and Taiho Pharmaceutical have formed a strategic partnership to optimize manufacturing technologies for next-generation antibody-drug conjugates using the AraLinQ platform, strengthening global ADC production capabilities.Fact-Checked
Mergers & AcquisitionsEvexta Bio and Roche Partner on Phase 1b Trial of Rupitasertib Plus Giredestrant in ESR1-Mutated Advanced Breast CancerEvexta Bio has signed a clinical collaboration and supply agreement with Roche to evaluate the all-oral combination of rupitasertib (a dual-node PAM pathway inhibitor) and giredestrant (an oral…Fact-Checked
Clinical TrialsAmplia and Lilly Partner to Advance Narmafotinib Plus Olomorasib for KRAS G12C-Mutant NSCLCAmplia Therapeutics has entered a clinical trial collaboration with Eli Lilly to evaluate the combination of the investigational FAK inhibitor narmafotinib and the KRAS G12C inhibitor olomorasib in…Fact-Checked
Mergers & AcquisitionsAbCellera, Vertex Sign Deal to Develop Autoimmune T-Cell EngagersAbCellera and Vertex Pharmaceuticals have formed a strategic collaboration to develop multispecific T-cell engagers for autoimmune diseases and other conditions.Fact-Checked
Mergers & AcquisitionsRelation, GSK Partner in $110M AI Drug Discovery CollaborationRelation and GSK have formed a strategic collaboration worth up to $110 million to generate large-scale human cellular perturbation datasets that will train AI foundation models, including MORGAN…Fact-Checked
Mergers & AcquisitionsJohnson & Johnson Partners with Sail Biomedicines for In Vivo CAR-T TherapiesJohnson & Johnson has entered a strategic collaboration with Sail Biomedicines to develop in vivo CAR-T therapies for immune-mediated diseases.Fact-Checked
Mergers & AcquisitionsCSL Reports Positive Phase 3b Results for ANDEMBRY in Children With HAECSL reported positive Phase 3b topline results for ANDEMBRY (garadacimab-gxii) in children aged 2 to 11 years with hereditary angioedema.Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.